Diagnostic Dilemma and Therapeutic Challenges in EWSR1::PATZ1 Fusion Sarcomas: Insights From Two Patients.
Sunil Pasricha, Sameer Rastogi, Divya Bansal et al.
✦ AI-curated · Sources linked
Case in brief
The report describes two patients with EWSR1::PATZ1 fusion sarcoma, a rare soft-tissue and bone round-cell sarcoma. The tumors showed conventional round-cell morphology and could express both myogenic and neurogenic markers, creating diagnostic overlap with other sarcomas. One patient was misdiagnosed as having synovial sarcoma and, on another occasion, rhabdomyosarcoma. The authors highlight the role of molecular testing, including next-generation sequencing, in establishing the diagnosis. The abstract does not provide treatment details or clinical outcomes; it notes that prognostic implications and therapeutic guidance remain uncertain.
What made this case unusual
One patient received two different initial diagnoses—synovial sarcoma and rhabdomyosarcoma—illustrating how the tumor’s morphology and marker expression can mislead classification.
Diagnostic / clinical pearl
When round-cell sarcoma morphology and myogenic or neurogenic marker expression leave the diagnosis uncertain, molecular testing for EWSR1::PATZ1 fusion can help distinguish this entity from mimics.
Why it matters
The report identifies unresolved prognostic and treatment questions and calls for larger collaborative studies to clarify them.